Soft Tissue Sarcoma Market Research Report Information By Type (Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (Gist), And Others), By Diagnosis And Treatment (Diagnosis(Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI),And Others), Magnetic Resonance Imaging (MRI)( Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs , Radiation Therapy, Surgery) , By End User (Hospitals And Clinics , Cancer Research Centers, And Others), and by Region (North America, Europe, Asia-Pacific, Middle East & Africa, and South Ameri

Global Soft Tissue Sarcoma Market Overview

Soft Tissue Sarcoma Market Size Was Valued At USD 3.43 Billion In 2024. The Global Soft Tissue Sarcoma Industry Is Projected To Grow From USD 3.64 Billion In 2025 To USD 7.69 Billion By 2035, Exhibiting A Compound Annual Growth Rate (CAGR) Of 7.67% During The Forecast Period (2024 - 2035).

Increasing Incidence Of Soft Tissue Sarcomas Rising Awarenes Associated With Soft Tissue Sarcoma And Growing Approval Of Innovative Treatment For Soft Tissue Sarcoma is driving the Global Soft Tissue Sarcoma Market.

As per Analyst at MRFR,” The increasing incidence of soft tissue sarcomas is significantly driving the growth of the market for related treatments and diagnostics. As the prevalence of these rare cancers rises, fueled by factors such as genetic predispositions, environmental influences, and lifestyle changes, there is a growing demand for innovative therapeutic options and advanced diagnostic technologies”

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Soft Tissue Sarcoma Market Trends

GROWING GERIATRIC POPULATION

The growing geriatric population is creating lucrative growth opportunities for the global soft tissue sarcoma market, as older adults are at a higher risk for developing various cancers, including soft tissue sarcomas. With an increasing number of individuals over the age of 65, the incidence of these rare tumors is expected to rise, leading to greater demand for effective diagnostic and treatment options. According to the PubMed study published in 2022, revealed that nearly 60% of soft tissue sarcoma arise in patients aged ≥65 years.

Furthermore, the increasing geriatric population in North America, Europe, and Asia-Pacific will create lucrative growth opportunities in the upcoming years. As per America’s Health Rankings, approximately 58 billion adults ages 65 and older were living in the US in 2022, and this number was projected to grow nearly 22% in the US in 2040. According to the European Commission, there were 448.8 billion people, and more than one fifth of them were aged 65 years and over in Europe. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 billion people aged 60 or older in Asia-Pacific in 2022. Also, it has been estimated that the number will double to approximately 1.3 billion people by 2050 in Asia-Pacific.

Soft Tissue Sarcoma Market Segment Insights

Global Soft Tissue Sarcoma Type Insights

Based on type, the Soft Tissue Sarcoma Market has been segmented into Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST) and Others. The Angiosarcoma segment held the largest market in 2024 and the Gastrointestinal Stromal Tumor (GIST) segment is the fastest growing segment during the forecast period.

Global Soft Tissue Sarcoma Diagnosis and Treatment Insights

Based on Diagnosis and Treatment, the Soft Tissue Sarcoma Market has been segmented into Diagnosis and Treatment. The Diagnostic segment held the largest market in 2024 and the Treatment segment is the fastest growing segment during the forecast period. Diagnosis further segmented into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others which include PET scan, X- Ray. Treatment further segmented into Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery.

Figure 1: Global Soft Tissue Sarcoma Market, by Diagnosis and Treatment, 2024 & 2035 (USD Billion)

Global Soft Tissue Sarcoma end user Insights

Based on End User, the Soft Tissue Sarcoma Market has been segmented into Hospitals and Clinics, Cancer Research Centers and others. The Hospitals and Clinics segment held the largest market in 2024 and is the fastest growing segment during the forecast period.

Global Soft Tissue Sarcoma Regional Insights

Based on region, the Soft Tissue Sarcoma Market has been segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America accounted for the largest market share in 2024 and is anticipated to reach USD 1,407.79 billion by 2035. However, Asia-Pacific is projected to grow at the highest CAGR of 10.05% during the forecast period. North America held the largest market share for soft tissue sarcoma in 2024 due to several key factors, including a well-established healthcare infrastructure, high awareness levels, and increased access to advanced treatment options. The region's strong presence of leading pharmaceutical companies and active research initiatives also contribute to market dominance. 

Rising incidence rates of soft tissue sarcoma, coupled with early diagnosis and favorable reimbursement policies, further support market growth. In addition, the U.S. government's investments in cancer research and the presence of organizations such as the National Cancer Institute (NCI) bolster innovation in therapies. By 2035, the North American soft tissue sarcoma market is projected to reach USD 1,407.79 billion, driven by continuous advancements in targeted therapies and personalized medicine. The growing aging population, along with increased clinical trials and drug approvals, will likely sustain this upward trajectory throughout the forecast period.

Asia-Pacific is projected to grow at the highest CAGR of 10.05% in the soft tissue sarcoma market during the forecast period due to several key drivers. Increasing healthcare expenditure, improving access to advanced cancer treatments, and growing awareness about rare cancers are boosting early diagnosis and treatment rates across the region. Rapid urbanization, a rising aging population, and changing lifestyles are contributing to a higher cancer burden. In addition, governments in countries like China, India, and Japan are investing heavily in healthcare infrastructure and expanding insurance coverage, making treatment more accessible. The growing presence of clinical research organizations (CROs) and increased participation in global clinical trials are fostering innovation and access to new therapies. As multinational pharmaceutical companies expand their footprint in Asia-Pacific, the region is set to become a major hub for oncology research and treatment growth.

Figure 2: Global Soft Tissue Sarcoma Market, by region, 2024 & 2035 (USD Billion)

Further, the major countries studied in the market report are the U.S., Canada, Mexico, Germany, France, Italy, UK, Spain, Japan, UAE, South Africa, Saudi Arabia, Argentina, and Brazil.

Global Soft Tissue Sarcoma Key Market Players & Competitive Insight

Many global, regional, and local vendors characterize the Soft Tissue Sarcoma Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major players in the market include GE HEALTHCARE, CANON MEDICAL SYSTEMS CORPORATION, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD., BLUEPRINT MEDICINES CORPORATION, JOHNSON & JOHNSON INC., BRISTOL-MYERS SQUIBB COMPANY, EISAI CO., LTD, SIEMENS HEALTHINEERS, ELI LILLY AND COMPANY, among others. The Soft Tissue Sarcoma Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

Key Companies in the Soft Tissue Sarcoma Market include.

• GE HEALTHCARE


• CANON MEDICAL SYSTEMS CORPORATION


• NOVARTIS AG


• HOFFMANN-LA ROCHE LTD.


• BLUEPRINT MEDICINES CORPORATION


• JOHNSON & JOHNSON INC.


• BRISTOL-MYERS SQUIBB COMPANY


• EISAI CO., LTD


• SIEMENS HEALTHINEERS


• ELI LILLY AND COMPANY

Global Soft Tissue Sarcoma Industry Developments

• In December 2022, Genentech, part of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for treating adult and pediatric patients aged two years and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).


• In January 2020, Blueprint Medicines Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) that contain a mutation in the platelet-derived growth factor receptor alpha (PDGFRA) exon 18, including the PDGFRA D842V mutation. AYVAKIT is the first precision therapy authorized to treat a specific genomic subset of GIST patients.


• In June 2021, Eisai and Bristol Myers Squibb formed a global strategic collaboration for Eisai’s MORAb-202 antibody-drug conjugate. MORAb-202 features Eisai’s proprietary antibody and payload, leveraging the company’s advanced chemistry expertise. Its unique payload is eribulin, a compound developed through modern synthetic organic chemistry, which has already benefited patients with breast cancer and soft tissue sarcoma.

Soft Tissue Sarcoma Market Segmentation

Soft Tissue Sarcoma Market by Type Outlook (USD Billion, 2019-2035)

• Angiosarcoma


• Epithelioid Sarcoma


• Gastrointestinal Stromal Tumor (GIST)


• Others

Soft Tissue Sarcoma Market by Diagnosis and Treatment Outlook (USD Billion, 2019-2035)

• Diagnosis
  
  
  
  • Biopsy                    
  
  
  • Ultrasound Scan               
  
  
  • Magnetic Resonance Imaging (MRI)
  
  
  • Others
  
  
  
  


• Treatment
  
  
  
  • Targeted Therapy
  
  
  • Chemotherapy         
  
  
  • Anti-Angiogenesis Drugs             
  
  
  • Radiation Therapy
  
  
  • Surgery
  
  
  
  

Soft Tissue Sarcoma Market by End User Outlook (USD Billion, 2019-2035)

• Hospitals and Clinics   


• Cancer Research Centers


• Others

Global Soft Tissue Sarcoma Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  • Mexico
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Spain
  
  
  • Italy
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East and Africa
  
  
  
  • Saudi Arabia
  
  
  • UAE
  
  
  • South Africa
  
  
  • Rest of Middle East and Africa
  
  
  
  


• South America
  
  
  
  • Argentina
  
  
  • Brazil
  
  
  • South America
  
  
  
  

Report Attribute/Metric	Details
Market Size 2024	USD 3.43 Billion
Market Size 2025	USD 3.64 Billion
Market Size 2035	USD 7.69 Billion
Compound Annual Growth Rate (CAGR)	7.67% (2024-2035)
Base Year	2024
Market Forecast Period	2025-2035
Historical Data	2019- 2024
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Type, By Diagnosis and Treatment, By End User and Region
Geographies Covered	North America, Europe, Asia-Pacific, Middle East & Africa, and South America.
Countries Covered	The U.S., Canada, Mexico, Germany, France, Italy, UK, Spain, China, Japan, India, UAE, South Africa, Saudi Arabia, Argentina, and Brazil.
Key Companies Profiled	GE HEALTHCARE, CANON MEDICAL SYSTEMS CORPORATION, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD., BLUEPRINT MEDICINES CORPORATION, JOHNSON & JOHNSON INC., BRISTOL-MYERS SQUIBB COMPANY, EISAI CO., LTD, SIEMENS HEALTHINEERS, ELI LILLY AND COMPANY, among others.
Key Market Opportunities	·         GROWING GERIATRIC POPULATION ·         INVESTMENTS IN RESEARCH AND DEVELOPMENT
Key Market Dynamics	·         INCREASING INCIDENCE OF SOFT TISSUE SARCOMAS ·         RISING AWARENESS ASSOCIATED WITH SOFT TISSUE SARCOMA